WRBY Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -3.61% compared to Warby Parker's net margin of --. Warby Parker's return on equity of -6.28% beat Perspective Therapeutics's return on equity of --.

Warby Parker has a consensus price target of $26.86, signalling upside risk potential of 81.47%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 638.1%. Given that Perspective Therapeutics has higher upside potential than Warby Parker, analysts believe Perspective Therapeutics is more attractive than Warby Parker.

Warby Parker has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Warby Parker has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Warby Parker quarterly revenues are $190.6M, which are larger than Perspective Therapeutics quarterly revenues of --. Warby Parker's net income of -$6.9M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Warby Parker's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker is 2.31x versus 12.62x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Daxor has a net margin of -3.61% compared to Warby Parker's net margin of --. Warby Parker's return on equity of -6.28% beat Daxor's return on equity of 1.57%.

Warby Parker has a consensus price target of $26.86, signalling upside risk potential of 81.47%. On the other hand Daxor has an analysts' consensus of $23.50 which suggests that it could grow by 192.03%. Given that Daxor has higher upside potential than Warby Parker, analysts believe Daxor is more attractive than Warby Parker.

Warby Parker has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Daxor has a beta of -0.059, suggesting its less volatile than the S&P 500 by 105.928%.

Warby Parker has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daxor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker pays -- of its earnings as a dividend. Daxor pays out -- of its earnings as a dividend.

Warby Parker quarterly revenues are $190.6M, which are larger than Daxor quarterly revenues of --. Warby Parker's net income of -$6.9M is higher than Daxor's net income of --. Notably, Warby Parker's price-to-earnings ratio is -- while Daxor's PE ratio is 25.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker is 2.31x versus 18.44x for Daxor. Usually stocks with elevated PS ratios are considered overvalued.

Precision Optics has a net margin of -3.61% compared to Warby Parker's net margin of -21.42%. Warby Parker's return on equity of -6.28% beat Precision Optics's return on equity of -38.36%.

Warby Parker has a consensus price target of $26.86, signalling upside risk potential of 81.47%. On the other hand Precision Optics has an analysts' consensus of -- which suggests that it could fall by --. Given that Warby Parker has higher upside potential than Precision Optics, analysts believe Warby Parker is more attractive than Precision Optics.

Warby Parker has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Precision Optics has a beta of 0.188, suggesting its less volatile than the S&P 500 by 81.244%.

Warby Parker has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision Optics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker pays -- of its earnings as a dividend. Precision Optics pays out -- of its earnings as a dividend.

Warby Parker quarterly revenues are $190.6M, which are larger than Precision Optics quarterly revenues of $4.5M. Warby Parker's net income of -$6.9M is lower than Precision Optics's net income of -$969.7K. Notably, Warby Parker's price-to-earnings ratio is -- while Precision Optics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker is 2.31x versus 1.30x for Precision Optics. Usually stocks with elevated PS ratios are considered overvalued.

Sanara MedTech has a net margin of -3.61% compared to Warby Parker's net margin of -5.85%. Warby Parker's return on equity of -6.28% beat Sanara MedTech's return on equity of -23.3%.

Warby Parker has a consensus price target of $26.86, signalling upside risk potential of 81.47%. On the other hand Sanara MedTech has an analysts' consensus of $48.50 which suggests that it could grow by 66.95%. Given that Warby Parker has higher upside potential than Sanara MedTech, analysts believe Warby Parker is more attractive than Sanara MedTech.

Warby Parker has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sanara MedTech has a beta of 1.470, suggesting its more volatile than the S&P 500 by 46.998%.

Warby Parker has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanara MedTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker pays -- of its earnings as a dividend. Sanara MedTech pays out -- of its earnings as a dividend.

Warby Parker quarterly revenues are $190.6M, which are larger than Sanara MedTech quarterly revenues of $26.3M. Warby Parker's net income of -$6.9M is lower than Sanara MedTech's net income of -$1.5M. Notably, Warby Parker's price-to-earnings ratio is -- while Sanara MedTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker is 2.31x versus 2.84x for Sanara MedTech. Usually stocks with elevated PS ratios are considered overvalued.